Madrigal Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.
Madrigal Pharmaceuticals has raised $1.1B across 3 funding rounds on record, the most recent an undisclosed round of $600M announced in Mar 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Madrigal Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Mar 2024.
Madrigal Pharmaceuticals Funding Rounds
Madrigal Pharmaceuticals raised $250M in a Post-IPO Debt announced in May 2022.
7 months later, an undisclosed round of $259M was announced in Dec 2022.
1.3 years later, an undisclosed round of $600M was announced in Mar 2024.
Madrigal Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Madrigal Pharmaceuticals Funding Compared to Other Biotechnology Startups
Madrigal Pharmaceuticals' latest round of $600M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Madrigal Pharmaceuticals in Biotechnology and Conshohocken
Companies Similar to Madrigal Pharmaceuticals
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Madrigal Pharmaceuticals Funding FAQs
What does Madrigal Pharmaceuticals do?
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.
How much funding has Madrigal Pharmaceuticals raised?
Madrigal Pharmaceuticals has raised $1.1B across 3 rounds on record. The most recent is an undisclosed round of $600M announced in Mar 2024.
When did Madrigal Pharmaceuticals last raise funding?
Madrigal Pharmaceuticals' most recent funding round on record is an undisclosed round of $600M, announced in Mar 2024.
Who founded Madrigal Pharmaceuticals?
FundedIQ lists Rebecca Taub (Founder) at Madrigal Pharmaceuticals.
Where is Madrigal Pharmaceuticals headquartered?
Madrigal Pharmaceuticals is based in Conshohocken, Pennsylvania, United States.
How many employees does Madrigal Pharmaceuticals have?
Madrigal Pharmaceuticals is in the 51-100 employee band.
How does Madrigal Pharmaceuticals' funding compare to other Biotechnology startups?
Madrigal Pharmaceuticals' latest round of $600M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Madrigal Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Madrigal Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.